Healthcare Industry News: endoscope
News Release - May 23, 2007
Mediscience Technology Corp/BioScopix Names Dr. Fredrick Naftolin Chief Medical OfficerCHERRY HILL, N.J.--(HSMN NewsFeed)--Mediscience Technology, Corp. (OTCBB:MDSC ) announced that Dr. Fredrick Naftolin joined the company as its Chief Medical Officer effective May 18, 2007. Dr. Naftolin has extensive medical Ob/Gyn health experience with specific interest in female endocrinology, diseases of the female reproductive system, Ob/Gyn research, cancer research, and biochemistry of cancer disease. His consultant responsibilities will include consultation as Chief Medical Advisor of MDSC New York subsidiary BioScopix, Inc. in the development and commercialization of MTC/Bio Autofluorescence-Based Diagnostic Methods and Equipment for human cancer screening and diagnosis, and female hormone level detection: e.g. CD-Ratiometer, CPE.
About Mediscience Technology/BioScopix Inc
Mediscience Technology Corporation and its New York subsidiary, BioScopix Inc., are engaged in the design, development and commercialization of medical devices that detect human cancers in vivo. Such detection is done through the use of Optical Biopsy techniques, wherein light of certain wavelengths is directed onto human tissue in the body, causing the tissue of the body to emit light that indicates whether the tissue is cancerous, benign, or normal. Optical Biopsy (OB) is based on optical spectroscopy for diagnosis of the molecular state of tissue (in vivo or ex vivo) without surgery or dyes. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other, more invasive, methods of cancer detection.
About Mediscience/BioScopix and Infotonics Technology Center
Mediscience/ BioScopix and the Infotonics Technology Center are engaged in the selective design, development and commercialization of MTC medical devices i.e. Capsule Diagnostics System (CPE) for GI tract cancer detection, and CD-Ratiometer (CDR) for detection of cancers and their related physiological changes using non-invasive technology (MTC Intellectual Property). This collaboration exclusively combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection in a Capsule or hand held endoscope format. Infotonics w/ MTC support is forming a high-performance Commercialization Program Team to transfer the photonic Capsule technology CPE from research to market in a timely manner, including commercial prototypes and pilot production for FDA trials. Infotonics will provide incubation office and lab space in the Infotonic Technology Center for Mediscience/BioScopix to accelerate the commercialization schedule.
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.
8-K SEC filing May 22, 2007 Naftolin employment agreement and abbreviated CV filing.
www.medisciencetech.com ref: Syracuse University Report dtd 2/26/2006
CITIGROUP/Smith Barney Analyst Report 10-1-2004 see Pg. 20
Source: Mediscience Technology
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.